Aug 13, 2020 8:00am EDT SCYNEXIS Announces Presentations at 2020 IDSOG Virtual Annual Meeting Highlighting Ibrexafungerp’s Potential for the Treatment of Vulvovaginal Candidiasis
Aug 10, 2020 8:20am EDT SCYNEXIS Reports Second Quarter 2020 Financial Results and Provides Company Update
Jul 29, 2020 8:00am EDT SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis
Jul 22, 2020 8:00am EDT SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of Ibrexafungerp
Jul 09, 2020 8:00am EDT SCYNEXIS to Host A Key Opinion Leader Discussion on the Immediate Need in Treating Women with Vaginal Yeast Infections
Jun 02, 2020 8:00am EDT SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales
May 11, 2020 8:50am EDT SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update
May 06, 2020 8:00am EDT SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp
